They are then infused back into the patient, with sometimes powerful results. Novartis’ CAR-T, Kymriah (tisagenlecleucel) was shown to be capable of noteworthy results, with a multi-centre ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

At Novartis, he led the U.S. Oncology business, overseeing flagship products such as Tasigna®, Gleevec®, and Kymriah®, and played a key role in integrating the GSK oncology portfolio.

Novartis’ Kymriah or Gilead Science’s Tecartus or Yescarta. After a median follow-up of 21.7 months, 5.8% of patients developed a second primary malignancy. Among 1,253 participants in four studies ...

Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that will be closely compared with a rival product from Eli Lilly. Novartis ...

The FDA yesterday approved Novartis’ Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers, significantly expanding the number of patients who will ...